July 22, 2015

NeoGenomics Expands Multimodality Cancer Profile Testing

Launches new Tumor-Type Specific Cancer Profiles and Next Generation Sequencing for Detecting Fusion Genes When FISH is not possible

FT. MYERS, Fla., July 22, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an expansion of its comprehensive multimodality NeoTYPE™ tumor-type specific cancer profiling tests to include new profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and for cancers of unknown primary ("CUP"). These new tests integrate a variety of technologies, including next generation sequencing, viral in-situ hybridization, FISH, and immunohistochemistry.

A number of new tests are being added to NeoGenomics cancer diagnostic test menu. HPV testing is being integrated with next generation sequencing (NGS) for head and neck cancer. A complete analysis of somatic mutations in BRCA1 and BRCA2 are now part of breast, ovarian and pancreatic cancer profiling to aid in selecting recently approved therapy for cancers with impaired DNA repair mechanism. Additionally, all profiles now include analysis of PD-L1 expression by immunohistochemistry.

In addition, NeoGenomics is now offering complete profiling for cancers of unknown primary. This profiling incorporates analysis using extensive immunohistochemistry, Next Generation Sequencing of 315 genes and 9 FISH probes. This comprehensive profiling of CUP provides information to help identify not only the potential origin of the tumor but, more importantly, provide information that helps in selecting therapy.

Also, profiling of Sarcoma for chromosomal translocations using Next Generation Sequencing is now available. Sarcoma is the most common type of cancer in pediatric patients and defining the type of chromosomal translocation helps in classification, predicting clinical course and therapy. While FISH testing remains the gold standard for analyzing chromosomal translocations in ALK, ROS1, and RET, the current profiling integrates the option of using NGS for detecting fusions in these genes when tissue is scant and FISH testing is not possible or is inconclusive.

Douglas VanOort, NeoGenomics' Chairman and Chief Executive Officer, stated "Innovation is a key focus of our company. As scientific and technological advances in cancer care are made, we try to quickly develop and update our testing services in order to provide the most important information to Physicians as they treat cancer patients."

Dr. Maher Albitar, the Company's Chief Medical Officer and Director of Research and

Development, commented "Profiling the driving biological abnormalities in a specific cancer is crucial when considering treatment options including immunotherapy and various other targeted therapies. NGS is a very powerful tool in this profiling. However, immunohistochemistry, FISH and other in-situ hybridization methods can add significant useful information. Our strategy is to take advantage of all available tools to provide treating physicians with all useful information for determining diagnosis, classification, prognosis, and therapy selection."

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of CLIA–certified clinical laboratories that specialize in cancer genetics testing, the fastest growing segment of the laboratory industry. The Company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States, and has laboratories in Nashville, TN; Irvine, Fresno and West Sacramento CA; and Tampa and Fort Myers, FL.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neogenomics-expands-multimodality-cancer-profile-testing-300116809.html

SOURCE NeoGenomics, Inc.